Form 4: Compass Therapeutics CEO Sells Shares for Tax Obligations

Compass Therapeutics CEO Thomas J. Schuetz disposed of 44,025 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Thomas J. Schuetz, Chief Executive Officer and Director of Compass Therapeutics, Inc. (CMPX), reported a disposition of common stock.
• On November 16, 2025, Mr. Schuetz disposed of 44,025 shares of CMPX common stock at a price of $4.83 per share.
• This transaction was a 'disposition to issuer to cover tax' (Transaction Code F), specifically for tax withholding obligations associated with the vesting of restricted stock units (RSUs).
• Following this transaction, Mr. Schuetz beneficially owns 6,436,800 shares of common stock.
• The filing also details unvested RSUs: 250,000 granted on February 8, 2023, with the first installment vested on February 8, 2024, and 478,125 granted on January 9, 2024, with the first installment vested on January 9, 2025. Both awards vest in four equal annual installments.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary event for tax withholding related to RSU vesting, which is neutral in terms of company performance or outlook.

Positives

• The transaction is a routine event related to compensation, not a discretionary sale by the insider.
• The CEO continues to hold a substantial number of shares (6,436,800), indicating continued alignment with shareholder interests.

Negatives

• A reduction in direct share ownership, even if for tax purposes.

Future Outlook

The filing indicates future vesting events for restricted stock units, with installments vesting annually according to the established schedules.

Industry Context

Routine insider transactions like tax-related dispositions of shares are common across all industries for executives receiving equity compensation. This specific filing does not provide broader industry context.

Comparison to Industry Standards

• This is a standard Form 4 filing for a tax withholding event related to RSU vesting, which is a common practice for executive compensation in publicly traded companies.

Related Party Transactions

• The transaction involves the CEO disposing of shares to the issuer (Compass Therapeutics, Inc.) to cover tax obligations, which is a standard, non-discretionary related party transaction.

Stakeholder Impact

• Shareholders: Minimal direct impact as it is a routine tax-related transaction, not a discretionary sale indicating a change in confidence. The CEO retains a significant stake.
• Management: The CEO's compensation structure includes equity, aligning interests with shareholders.

Next Steps

• Future annual vesting of the remaining restricted stock units granted on February 8, 2023, and January 9, 2024.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary disposition of shares by the CEO to cover tax withholding obligations upon RSU vesting. It does not reflect a change in management's confidence or the company's fundamentals. The CEO retains a substantial beneficial ownership, indicating continued alignment. Therefore, this specific filing does not warrant a change in investment thesis, and a 'hold' recommendation is appropriate based solely on this information.

Keywords

Compass Therapeutics, CMPX, Thomas J. Schuetz, Form 4, insider transaction, stock sale, restricted stock units, RSU vesting, tax withholding, CEO, director, beneficial ownership